Simiao Zhao
赵思邈
Simiao Zhao (赵思邈) is the founder and CEO of EonArk (无尽方舟), an AI-driven longevity drug R&D company he co-founded in Shenzhen in mid-2026 with UC Berkeley postdoc Jingkun Zeng, who serves as CTO — Zhao was 27 at the time. He holds a PhD from Oxford focused on AI for medicine, and Zeng studied under Nobel laureate Jennifer Doudna; per Unity Ventures (九合创投), which participated in the company's tens-of-millions-yuan seed round and led its seed+ round within the same month, EonArk works on AI-powered anti-aging drug development. Beyond the EonArk founding story, elsewhere's corpus doesn't yet carry a fuller profile of Zhao.
AI-generated — may contain errors, please verify.
Coverage
AI longevity biotech startup EonArk raises two rounds in one month, with Unity Ventures leading seed+ round | Unity Ventures portfolio
Oxford PhD Launches Startup, Using Data, AI, and Biotechnology to Explore the Future of Longevity and Health
Unity Ventures Early Bet Momenta Files for Hong Kong IPO, Over a Dozen Portfolio Companies Announce Funding Rounds | Unity Ventures Summer Review
From Embodied Artificial Intelligence and world models to controlled nuclear fusion and quantum computing, the frontier of exploration knows no bounds.
Immortality: Starting with Dogs
Death is not an inevitable law of nature — just an engineering problem.
